Using DECoN (which stands for Detection of Exon Copy Number variants), the researchers took advantage of the high density of sequencing data available in
new gene panels to accurately detect deletions or duplications of exons.
Not exact matches
Predicine has launched a
new liquid biopsy
panel called PredicineATLAS, which covers 600
genes and offers a readout of patients tumor mutational burden to help inform and assess immuno - oncology treatment.
Altering
genes is illegal in the United States and part of Europe, so the
panel's
new recommendation could be the beginning of a political fight that would likely see loud opposition from Christians and other religious groups.
Using
new gene editing techniques like CRISPR / Cas9 to treat genetic diseases is fine under certain conditions, but it should not be used to enhance people, a
panel of experts says.
It currently analyses a
panel of multiple cancer predisposition
genes thanks to
new - generation sequencing techniques.
Invivoscribe's clinical laboratories also offer comprehensive MyAML ®, MyHeme ®, MyMRD ®, and custom
gene panels, that when used in combination with Invivoscribe's proprietary MyInformatics ® Software can identify and track primary driver mutations as well as the subclonal architecture and emergence of
new driver mutations in patients with hematologic disease.
Invivoscribe also offers comprehensive MyAML ®, MyHeme ®, MyMRD ®, and custom
gene panels, that when used in combination with Invivoscribe's proprietary MyInformatics ® Software can identify and track primary driver mutations as well as the subclonal architecture and emergence of
new driver mutations in patients with hematologic disease.
After clicking on any of the
panels, for example on the top left
panel marked with a red asterisk, the expression profiles of the individual
genes that follow the corresponding pattern as well as their names appear in a
new window (as shown in B).
Clicking on this graph opens a
new window with the corresponding
genes (bottom
panel).
In a report published in the
New England Journal of Medicine, scientists say that a
panel of 20
genes can distinguish the more common localized prostate cancer that grows slowly and rarely spreads from the more aggressive type that can spread quickly.